EN DE
STOCK COMPARISON

Panagene vs MEDIPOST Co.: Fair Value & Quality

Both stocks run through our valuation models. Here is how Panagene (046210) and MEDIPOST Co. (078160) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees Panagene as the less overvalued of the two: Panagene trades at KRW 1,106 versus a fair value of KRW 480 (-57%), while MEDIPOST Co. trades at KRW 9,850 versus KRW 3,628 (-63%).
Panagene
046210.KQ · KRW · Health Care
-57%
upside to fair value
overvalued
PriceKRW 1,106
Fair ValueKRW 480
Quality27/100
MEDIPOST Co.
078160.KQ · KRW · Health Care
-63%
upside to fair value
overvalued
PriceKRW 9,850
Fair ValueKRW 3,628
Quality26/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

PanageneMEDIPOST Co.
Profitability
-19%Net margin4%
-12%Operating margin-26%
-441%Return on equity—
-8%Return on assets-3%
Growth
-72%Revenue growth (YoY)23%
2.0%Avg. growth/yr (3Y)4.7%
-1.5%Avg. growth/yr (5Y)8.7%
Balance & size
0.02×Debt / equity0.03×
$38MMarket cap$240M
weakGrowth qualityexpensive

MEDIPOST Co. leads: 2 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Panageneof which business quality 27 · market factors 13 MEDIPOST Co.of which business quality 26 · market factors 18
ProfitabilityMargins and returns on capital today
6
4
Quality GrowthAre margins and returns improving?
42
32
CashflowEarnings quality: real cash, not paper profit
1
4
Fin. StrengthBalance sheet, leverage, solvency risk
84
59
InvestmentDisciplined investing over empire-building
14
72
Low VolatilityCalm price path (market factor)
37
39
MomentumPrice trend over the last 3–12 months (market factor)
2
5
52W MomentumDistance to the 52-week high (market factor)
3
15
Net IssuanceBuybacks instead of dilution
9
0

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Panagene

Asset-BasedKRW 1,074

1 of 1 models see the stock below the current price.

MEDIPOST Co.

Asset-BasedKRW 4,269

1 of 1 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Panagene
Bear KRW 317Fair Value KRW 480Bull KRW 600
KRW 1,106 = current price (white tick)
MEDIPOST Co.
Bear KRW 2,708Fair Value KRW 3,628Bull KRW 5,415
KRW 9,850 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Panagene · Health Care

Quality score27 · bottom 25%
Fair value upside-57% · below median

MEDIPOST Co. · Health Care

Quality score26 · bottom 25%
Fair value upside-63% · bottom 25%

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees Panagene as the less overvalued of the two: Panagene trades at KRW 1,106 versus a fair value of KRW 480 (-57%), while MEDIPOST Co. trades at KRW 9,850 versus KRW 3,628 (-63%).

Panagene has the higher quality score (27/100).

See the full analysis →
Panagene · MEDIPOST Co.

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Panagene

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to MEDIPOST Co.

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.